329 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
with severe immune-mediated diseases like ITP. These pivotal results are a testament to our commitment and expertise in rare blood diseases and ability
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
of credit or loan commitments, the “original amount” of the loan is the size of the line of credit or loan commitment when the line of credit or loan … commitment was most recently approved, extended, or renewed prior to the report date. However, if the amount currently outstanding as of the report
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
innovative MOAs in 8 dermatologic indications underscoring our commitment to patients with high unmet medical needs.”
The aggregated safety profile
6-K
EX-99.1
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
commitment to provide job security and salary continuation for at least a year after diagnosis. Today, we also support every Sanofi employee facing
6-K
EX-99.1
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
compared to placebo
Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing … of this disease. Today’s approval underscores our commitment to bringing therapies to young patients with unmet needs and also brings hope to these patients
6-K
EX-99.1
8rfgo7y
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
so1z8krxkagkkrvoyxfp
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.5
b00qxrqozwv6p4vb38iv
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
zxdqaw c1ggzs0286
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
jspnfnevv o1n4x6oj
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
b6cnxyqtlfr7diyn
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.3
rf9u mq7bowi
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
s0vwmyd 3aq3zn
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
l9p6yjoavmfjuxl2
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.2
ckew if764hvpxy
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.2
tsfllwvrwvvv2x
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
i70sk0au cl5ktly7rt3
27 Sep 23
Current report (foreign)
6:06am
6-K
s9alzf5m764miqnx2g2
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
rp2our ge68jzs3h3
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.1
ilgkjm
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm